Martine Cohen Solal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6502712/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Bone Fragility in Chronic Kidney Disease Stage 3 to 5: The Use of Vitamin D Supplementation. Metabolites, 2022, 12, 266.	2.9	3
2	<i>WNT11,</i> a new gene associated with early onset osteoporosis, is required for osteoblastogenesis. Human Molecular Genetics, 2022, 31, 1622-1634.	2.9	7
3	Managing Musculoskeletal and Kidney Aging: A Call for Holistic Insights. Clinical Interventions in Aging, 2022, Volume 17, 717-732.	2.9	0
4	Bone Fragility Fractures in CKD Patients. Calcified Tissue International, 2021, 108, 539-550.	3.1	25
5	Effect of Rubus idaeus Extracts in Murine Chondrocytes and Explants. Biomolecules, 2021, 11, 245.	4.0	1
6	The Role of Bone Biopsy in the Management of CKD-MBD. Calcified Tissue International, 2021, 108, 528-538.	3.1	14
7	Longitudinal Bone Loss Occurs at the Radius in CKD. Kidney International Reports, 2021, 6, 1525-1536.	0.8	8
8	Compromised Volumetric Bone Density and Microarchitecture in Men With Congenital Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3312-e3326.	3.6	10
9	The Role of Bone Biopsy in the Management of CKD-MBD: CKD-Related Osteoporosis or CKD-MBD/Osteoporosis?. Calcified Tissue International, 2021, 109, 112-112.	3.1	1
10	The Use of Imaging Techniques in Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBD)—A Systematic Review. Diagnostics, 2021, 11, 772.	2.6	7
11	More severe phenotype of earlyâ€onset osteoporosis associated with recessive form of <i>LRP5</i> and combination with <i>DKK1</i> or <i>WNT3A</i> . Molecular Genetics & Genomic Medicine, 2021, 9, e1681.	1.2	6
12	FC 079HIGH SERUM PHOSPHATE, A NOVEL POTENTIAL RISK FACTOR FOR BONE FRAGILITY FRACTURES IN THE COSMOS STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
13	A review and perspective on the assessment, management and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease. Endocrine, 2021, 73, 509-529.	2.3	15
14	Interactions between cadmium and zinc on gene expression pattern of differentiation markers in MC3T3-E1 cell line. Xenobiotica, 2021, 51, 1038-1046.	1.1	1
15	Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. RMD Open, 2021, 7, e001714.	3.8	26
16	Inhibition of sphingosine 1-phosphate protects mice against chondrocyte catabolism and osteoarthritis. Osteoarthritis and Cartilage, 2021, 29, 1335-1345.	1.3	10
17	Mechanical loading activates the YAP/TAZ pathway and chemokine expression in the MLO-Y4 osteocyte-like cell line. Laboratory Investigation, 2021, 101, 1597-1604.	3.7	14
18	Inadequate response to treatment reveals persistent osteoclast bone resorption in osteoporotic patients. Bone, 2021, 153, 116167.	2.9	2

#	Article	IF	CITATIONS
19	YAP/TAZ in Bone and Cartilage Biology. Frontiers in Cell and Developmental Biology, 2021, 9, 788773.	3.7	13
20	A loosening prosthesis in a dialysis patient. CKJ: Clinical Kidney Journal, 2020, 13, 897-899.	2.9	0
21	Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1682-1699.	3.6	53
22	Identification of TGFÎ ² signatures in six murine models mimicking different osteoarthritis clinical phenotypes. Osteoarthritis and Cartilage, 2020, 28, 1373-1384.	1.3	7
23	Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-11² activation on macrophages. Annals of the Rheumatic Diseases, 2020, 79, 1506-1514.	0.9	72
24	Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases. Journal of Clinical Medicine, 2020, 9, 3439.	2.4	50
25	Cortical Bone Microarchitecture in Dialysis Patients. American Journal of Nephrology, 2020, 51, 833-838.	3.1	4
26	Cherubism as a systemic skeletal disease: evidence from an aggressive case. BMC Musculoskeletal Disorders, 2020, 21, 564.	1.9	2
27	Heparan sulfate functions are altered in the osteoarthritic cartilage. Arthritis Research and Therapy, 2020, 22, 283.	3.5	14
28	Fragilidad Ã ³ sea e insuficiencia renal. EMC - Aparato Locomotor, 2020, 53, 1-9.	0.1	0
29	Lumbar spinal stenosis and disc alterations affect the upper lumbar spine in adults with achondroplasia. Scientific Reports, 2020, 10, 4699.	3.3	12
30	Galectin 3 Deficiency Alters Chondrocyte Primary Cilium Formation and Exacerbates Cartilage Destruction via Mitochondrial Apoptosis. International Journal of Molecular Sciences, 2020, 21, 1486.	4.1	12
31	Disruption of Bone Zinc Metabolism during Postnatal Development of Rats after Early Life Exposure to Cadmium. International Journal of Molecular Sciences, 2020, 21, 1218.	4.1	10
32	Relation Between PTH and Biochemical Markers of MBD. , 2020, , 103-116.		1
33	L'épaississement tendineux de l'arthropathie liée à la dialyse correspond à des dépôts amyloÃ⁻des Du Rhumatisme (Edition Francaise), 2019, 86, 604-609.	. Revue 0.0	0
34	Pycnodysostosis: Natural history and management guidelines from 27 French cases and a literature review. Clinical Genetics, 2019, 96, 309-316.	2.0	31
35	Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. Calcified Tissue International, 2019, 105, 271-284.	3.1	102
36	Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in Osteoclasts. Cancers, 2019, 11, 261.	3.7	11

#	Article	IF	CITATIONS
37	Microcracks in subchondral bone plate is linked to less cartilage damage. Bone, 2019, 123, 1-7.	2.9	20
38	OP0303â€MONOSODIUM URATE AND CALCIUM PYROPHOSPHATE CRYSTAL-INDUCED INTERLEUKIN 1 PRODUCTION DEPENDS ON GLUCOSE UPTAKE THROUGH GLUT1 TRANSPORTER. , 2019, , .		0
39	AB0087â€DLX5 AND DLX6 PROMOTES THE COMMITMENT OF MSC TO OSTEOBLASTIC LINEAGE AND CORTIC BONE FORMATION. , 2019, , .	AL	0
40	Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. CKJ: Clinical Kidney Journal, 2019, 12, 269-280.	2.9	29
41	Secular trends of hip fractures in France: impact of changing characteristics of the background population. Osteoporosis International, 2019, 30, 355-362.	3.1	18
42	Not all hyperphosphataemias should be treated. Nephrology Dialysis Transplantation, 2019, 34, 1077-1079.	0.7	2
43	Tendon thickening in dialysis-related joint arthritis is due to amyloid deposits at the surface of the tendon. Joint Bone Spine, 2019, 86, 233-238.	1.6	9
44	What are the predictors of clinical success after percutaneous vertebroplasty for osteoporotic vertebral fractures?. European Radiology, 2018, 28, 2735-2742.	4.5	10
45	Teenagers and young adults with nephropathic cystinosis display significant bone disease and cortical impairment. Pediatric Nephrology, 2018, 33, 1165-1172.	1.7	16
46	Genetic and Molecular Insights Into Genotype-Phenotype Relationships in Osteopathia Striata With Cranial Sclerosis (OSCS) Through the Analysis of Novel Mouse Wtx Mutant Alleles. Journal of Bone and Mineral Research, 2018, 33, 875-887.	2.8	10
47	The Authors Reply. Kidney International, 2018, 93, 1247.	5.2	0
48	The Authors Reply. Kidney International, 2018, 93, 1248-1249.	5.2	0
49	Blockage of sphingosin 1 phosphate S1P/S1PR pathway prevents from osteoarthritis in mice by reducing chondrocyte catabolism. Osteoarthritis and Cartilage, 2018, 26, S67.	1.3	0
50	Anterior Skull Base and Pericranial Flap Ossification after Frontofacial Monobloc Advancement. Plastic and Reconstructive Surgery, 2018, 141, 437-445.	1.4	17
51	Primary Osteoporosis in Young Adults: Genetic Basis and Identification of Novel Variants in Causal Genes. JBMR Plus, 2018, 2, 12-21.	2.7	43
52	The Expanding Life and Functions of Osteogenic Cells: From Simple Bone-Making Cells to Multifunctional Cells and Beyond. Journal of Bone and Mineral Research, 2018, 33, 199-210.	2.8	9
53	Iron-enriched diet contributes to early onset of osteoporotic phenotype in a mouse model of hereditary hemochromatosis. PLoS ONE, 2018, 13, e0207441.	2.5	20
54	Inflammatory Potential of Four Different Phases of Calcium Pyrophosphate Relies on NF-κB Activation and MAPK Pathways. Frontiers in Immunology, 2018, 9, 2248.	4.8	41

#	Article	IF	CITATIONS
55	Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease. Haematologica, 2018, 103, 1359-1368.	3.5	14
56	Chondrocyte Lin28a overexpression protects chondrocyte from osteoarthritis phenotype. Osteoarthritis and Cartilage, 2018, 26, S66-S67.	1.3	0
57	Proprotein convertase furin inhibits matrix metalloproteinase 13 in a TGFβ-dependent manner and limits osteoarthritis in mice. Scientific Reports, 2018, 8, 10488.	3.3	9
58	Porcupine inhibitors impair trabecular and cortical bone mass and strength in mice. Journal of Endocrinology, 2018, 238, 13-23.	2.6	37
59	Calpain-6 controls the fate of sarcoma stem cells by promoting autophagy and preventing senescence. JCI Insight, 2018, 3, .	5.0	21
60	OP0189â€Identification of new and rare variants in abcg2, slc22a1 and aldh16a1 genes in crystal-proven early-onset gout. , 2018, , .		0
61	THU0702â€Secular trends of hip fractures in france between 2002 and 2013: impact of the reference values. , 2018, , .		0
62	Systemic inhibition of IL-6/Stat3 signalling protects against experimental osteoarthritis. Annals of the Rheumatic Diseases, 2017, 76, 748-755.	0.9	251
63	Evaluation of fracture risk in chronic kidney disease. Journal of Nephrology, 2017, 30, 653-661.	2.0	27
64	Identification of a p.Arg708Gln variant in COL1A2 in atypical femoral fractures. Joint Bone Spine, 2017, 84, 715-718.	1.6	17
65	Fractures in patients with CKD—diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation. Kidney International, 2017, 92, 1343-1355.	5.2	151
66	Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone, 2017, 105, 11-17.	2.9	373
67	Dmp1 Promoter-Driven Diphtheria Toxin Receptor Transgene Expression Directs Unforeseen Effects in Multiple Tissues. International Journal of Molecular Sciences, 2017, 18, 29.	4.1	6
68	Etelcalcetide: injectable calcimimetic for the treatment of secondary hyperparathyroidism in hemodialysis-dependent patients. Drugs of Today, 2017, 53, 489.	1.1	2
69	Implication du gène LRP5 dans l'ostéoporose idiopathique de l'adulte jeune. Revue Du Rhumatisme (Edition Francaise), 2016, 83, A152-A153.	0.0	0
70	Dementia is a major risk factor for hip fractures in patients with chronic kidney disease. Osteoporosis International, 2016, 27, 1665-1669.	3.1	28
71	Interaction of HIF1α and β-catenin inhibits matrix metalloproteinase 13 expression and prevents cartilage damage in mice. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 5453-5458.	7.1	94
72	Role of ERα in the Effect of Estradiol on Cancellous and Cortical Femoral Bone in Growing Female Mice. Endocrinology, 2016, 157, 2533-2544.	2.8	20

#	Article	IF	CITATIONS
73	Sclerostin and Bone Aging: A Mini-Review. Gerontology, 2016, 62, 618-623.	2.8	37
74	SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma. Oncotarget, 2016, 7, 30712-30729.	1.8	19
75	OP0253â€Galectin 3 Defiency Altered Chondrocyte Primary Cilia formation and Exacerbated Cartilage Destruction. Annals of the Rheumatic Diseases, 2015, 74, 167.2-168.	0.9	0
76	Subchondral bone and osteoarthritis. Current Opinion in Rheumatology, 2015, 27, 420-426.	4.3	97
77	Loss of sclerostin promotes osteoarthritis in mice via \hat{l}^2 -catenin-dependent and -independent Wnt pathways. Arthritis Research and Therapy, 2015, 17, 24.	3.5	94
78	Molecular diagnosis of hypophosphatasia and differential diagnosis by targeted Next Generation Sequencing. Molecular Genetics and Metabolism, 2015, 116, 215-220.	1.1	54
79	Dkkâ€1–Mediated Inhibition of Wnt Signaling in Bone Ameliorates Osteoarthritis in Mice. Arthritis and Rheumatology, 2014, 66, 3028-3039.	5.6	114
80	When, How, and Why a Bone Biopsy Should Be Performed in Patients With Chronic Kidney Disease. Seminars in Nephrology, 2014, 34, 612-625.	1.6	53
81	Incidence and risk factors for hip fractures in dialysis patients. Osteoporosis International, 2014, 25, 159-165.	3.1	98
82	SAT0569â€Galectin 3 Exerts A Protective Role in A Murine Model of Osteoarthritis. Annals of the Rheumatic Diseases, 2014, 73, 796.2-796.	0.9	0
83	Prise en charge des fractures des hémodialysés. Revue Du Rhumatisme Monographies, 2013, 80, 74-77.	0.0	Ο
84	Animal models of osteoarthritis for the understanding of the bone contribution. BoneKEy Reports, 2013, 2, 422.	2.7	18
85	Protective role of systemic furin in immune response–induced arthritis. Arthritis and Rheumatism, 2012, 64, 2878-2886.	6.7	32
86	Animal models in OA: a means to explore bone. Osteoporosis International, 2012, 23, 853-856.	3.1	4
87	Does hormone replacement therapy prevent lateral rotatory spondylolisthesis in postmenopausal women?. European Spine Journal, 2012, 21, 1127-1134.	2.2	13
88	Subtrochanteric/femoral shaft Versus hip fractures: Incidences and identification of risk factors. Journal of Bone and Mineral Research, 2012, 27, 130-137.	2.8	22
89	Crosstalk between cartilage and bone: When bone cytokines matter. Cytokine and Growth Factor Reviews, 2011, 22, 91-97.	7.2	71
90	Remodelage osseux et traitements diurétiques. Revue Du Rhumatisme Monographies, 2011, 78, 124-128.	0.0	0

6

#	Article	IF	CITATIONS
91	Annexin 5 overexpression increased articular chondrocyte apoptosis induced by basic calcium phosphate crystals. Annals of the Rheumatic Diseases, 2008, 67, 1617-1625.	0.9	39
92	LRP5 gene polymorphisms and idiopathic osteoporosis in men. Bone, 2005, 37, 770-775.	2.9	73
93	Osteoporosis in chronic kidney disease. American Journal of Kidney Diseases, 2004, 43, 566-571.	1.9	189
94	Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrology Dialysis Transplantation, 2003, 18, 2325-2331.	0.7	144
95	A Phase 3 randomized, double-blind, placebo-controlled study investigating the efficacy and safety of Burosumab, an anti-FGF23 antibody, in adult X-Linked Hypophosphatemia (XLH). Endocrine Abstracts, O, ,	0.0	0